Skip to content

André Malbergier

2 papers in the library · 1 citation · publishing 2023-2026

Papers

Brief report: Ketamine-assisted "bridge therapy" for opioid tapering in complex cases.

The American journal on addictions January 28, 2026 Mariana C De Oliveira, Cláudia C De Araujo Palmeira, André B Negrão et al. 1 citation

A 25-year-old woman with opioid use disorder, chronic pain, and major depressive disorder received eight weekly intravenous ketamine infusions (0.5 mg/kg) alongside a gradual reduction of her methadone dose. After the protocol, her methadone dosage was cut by 50%, and she experienced better control of pain and cravings, fewer withdrawal symptoms, and increased participation in psychotherapy. The report suggests that ketamine-assisted bridge therapy may help support opioid tapering in patients with multiple co-occurring conditions.

Toxicity of Synthetic Cannabinoids in K2/Spice: A Systematic Review.

Brain sciences June 24, 2023 Mariana Campello De Oliveira, Mariana Capelo Vides, Dângela Layne Silva Lassi et al.

Synthetic cannabinoids (SCs), sold as 'K2', 'K9', or 'Spice', pose greater health risks than cannabis, with higher toxicity and addiction potential unrelated to Δ9-THC. A systematic review of 64 articles (10 original papers and 54 case studies) found that SCs, particularly AB-CHMINACA and MDMB-CHMICA, were linked to deaths, with tachycardia and seizures as the most common toxicity symptoms. Third-generation SCs showed higher prevalence of neuropsychiatric symptoms. SCs may exhibit greater toxicity and longer-lasting effects than THC, especially harmful for people with epilepsy and schizophrenia due to increased risk of psychiatric and neurologic disorders, convulsive crises, consciousness decline, and hemodynamic changes.